

Peter Woon-Hsi Chen, PhD
Department of Ophthalmology
UT Southwestern Medical Center
5323 Harry Hines Blvd.
Dallas, TX 75390-9057
T: 214-648-3677
Peter.Chen@utsouthwestern.edu

EDUCATION:

1986 B.A.	The University of Texas at Austin.
1991 M.S. (Immunology)	The University of Texas Health Science Center, at Houston, Graduate School of Biomedical Sciences, M.D. Anderson Cancer Center
1993 Ph.D. (Immunology)	The University of Texas Health Science Center, at Houston, Graduate School of Biomedical Sciences, M.D. Anderson Cancer Center

POSTDOCTORAL TRAINING:

Research Fellowships:

1994-1998	Postdoctoral Fellow, Schepens Eye Research Institute, Boston, MA Department of Ophthalmology, Harvard Medical School, Boston, MA
-----------	---

FACULTY POSITIONS:

1998-2004	Investigator, Schepens Eye Research Institute, Boston, MA
1999-2004	Instructor, Department of Ophthalmology, Harvard Medical School, Boston, MA
2004-present	Assistant Professor, Department of Ophthalmology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX
2007-present	Faculty, UT Southwestern Graduate School of Biomedical Sciences, Immunology Program
2008-present	Faculty, UT Southwestern Graduate School of Biomedical Sciences, Genetics and Development Program
2008-present	Member, UT Southwestern Simmons Cancer Center Research Faculty

PROJECT FUNDING

Principle Investigator

NEI RO1 EY017198	Epigenetic Gene Regulation by the Ocular Environment. 2/1/2007 - 1/31/2012
------------------	---

NEI RO1 EY017198-03S1	ARRA Supplement for Epigenetic Gene Regulation by the Ocular Environment
-----------------------	--

Co-Investigator

NEI RO1 CA30276-27	Immunological Modulation of Ocular Tumor Metastases 7/01/1981 - 5/31/2012
--------------------	--

Principal Investigator: Jerry Y. Niederkorn, Ph.D.,

NEI RO1 EY07641-21 Immunobiology of Corneal Allografts
8/01/1988 - 8/31/2012
Principal Investigator: Jerry Y. Niederkorn, Ph.D.

NEI P30EY020799-01 Core Grant for Vision Research
6/1/2010 - 5/31/2016
Principal Investigator: Jerry Y. Niederkorn, Ph.D.

AWARDS AND HONORS:

1989 R. E. "Bob" Smith Predoctoral Fellowship
1989 Graduate School of Biomedical Sciences Travel Award
1990 American Association for Cancer Research Travel Award
1991 Texas Immunology Conference Travel Award
1991-1993 NIH Predoctoral Immunology Training Grant
1993 Sowell-Huggins Scholar, The University of Texas Health Science Center
at Houston, Graduate School of Biomedical Sciences
1995-1997 National Research Service Award, 1 F32 EY6606-01, NIH-NEI
1995 Bristol-Meyers Oncology Division Travel Award
1996-1997 Fight for Sight Research Fellowship
1998 National Eye Institute Travel Grant
1998 International Society for Eye Research Travel Fellowship

MAJOR COMMITTEE ASSIGNMENTS:

1992-1993 Graduate School of Biomedical Sciences Curriculum Committee
1992-1993 Graduate School of Biomedical Sciences Immunology Program
Committee – Student Representative
1997-2000 Computer and Library Resources Committee- Schepens Eye Research
Institute
1998-2004 Institution Animal Care and Use Committee - Schepens Eye Research
Institute
2009- Chair, Immunology Program Postdoctoral Fellowship Steering Committee
UT Southwestern Medical Center, Graduate School of Biomedical
Sciences
2010- NIH, NEI Study Section (AED) ad hoc

MEMBERSHIPS IN PROFESSIONAL SOCIETIES:

American Association of Immunology
Association for Research in Vision and Ophthalmology
International Society for Eye Research
American Association for Cancer Research

MAJOR RESEARCH INTERESTS:

1. Epigenetic gene regulation in the ocular environment
2. Molecular mechanisms of corneal diseases
3. Immunobiology of corneal transplantation
4. Immunobiology and immunotherapy of ocular tumors
5. Immunobiology of age-related macular degeneration

TRAINING EXPERIENCE:

Undergraduate Students

Sofia Velez, Harvard University, Cambridge, MA, 1997.

Predoctoral Students (Mentorship and Committees) :

Jacobus J.J. Bosch, Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, University of Leiden Medical Center, Leiden, The Netherlands, 1999-2002. (Mentor)

Hanneke M. Mensink, Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, University of Leiden Medical Center, Leiden, The Netherlands, 2001-2002. (Mentor)

Carolien L. Lindenhovius, Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, University of Leiden Medical Center, Leiden, The Netherlands, 2002. (Co-mentor)

Dru Dace, The University of Texas Southwestern Medical Center, Graduate Immunology Program (Ph.D.), 2003-2006. (Co-mentor; Dissertation Committee)

Terry Coursey, The University of Texas Southwestern Medical Center, Graduate Immunology Program (Ph.D.), 2006 - present. (Co-mentor; Dissertation Committee, Chair)

Jacobus J.J. Bosch, M.D., University of Maryland, Baltimore County (Ph.D.), University of Leiden Medical Center, Leiden, The Netherlands, 2006 – present. (Dissertation Committee)

Nancy Reyes, The University of Texas Southwestern Medical Center, Graduate Immunology Program (Ph.D.), 2007 - present. (Co-mentor; Dissertation Committee, Chair)

Khrishen Cunnusamy, The University of Texas Southwestern Medical Center, Integrated Biology Program (Ph.D.), 2007 - 2011. (Co-mentor; Dissertation Committee)

Alina Montalbano, The University of Texas Southwestern Medical Center, Graduate Immunology Program (Ph.D.), 2008 - 2010. (Co-mentor; Dissertation Committee)

Kathryn Paunicka, The University of Texas Southwestern Medical Center, Graduate Immunology Program (Ph.D.), 2008 - present. (Co-mentor; Dissertation Committee, Chair)

Leila Sadegh, The University of Texas Southwestern Medical Center, Graduate Immunology Program (Ph.D.), 2009 - present. (Mentor)

Postdoctoral Fellows:

Wanhua Yang, Department of Ophthalmology, The University of Texas Southwestern Medical Center, 2006 – 2009. (Co-mentor)

Teaching Experience:

Schepens Eye Research Institute

Introduction to Immunology, 2002-2003.

Ocular Tumor Immunology, 2002-2003.

UT Southwestern Medical Center, Graduate School of Biomedical Sciences

Ethics in Research for Graduate Students, 2009-present.

Tumor Immunobiology (Non-immunology program graduate students), 2009-present.

Tumor Immunology (MD/PhD track medical students), 2009-present.

BIBLIOGRAPHY

1. Chen PW, Kaba DS, Ananthaswamy HN. Immune response to somatic cell hybrids between UV-induced regressor and spontaneous progressor C3H mouse tumor cells. *Cancer Res.*, 50:1544-49, 1990.
2. Fernandez A, Chen PW, Aggarwal BB, Ananthaswamy HN. Resistance of Ha-*ras* oncogene-induced progressor variants to tumor necrosis factor and interferon- γ . *Lymphokine Cytokine Res.*, 11:79-85, 1992.
3. Chen PW, Ananthaswamy HN. Abrogation of tumorigenicity and induction of cross-protective immunity in murine melanoma cells transfected with major histocompatibility complex class I and class II genes. *J. Immunol.*, 151:244-256, 1993.
4. Fernandez A, Chen PW, Ananthaswamy HN. *ras*-Induced neoplastic transformation and sensitivity to tumor necrosis factor. *Anticancer Res.*, 1994; 14:2649-2652.
5. Chen PW, Ananthaswamy HN. Antigen presentation by MHC class I and class II transfected K1735 murine melanoma cells. *J. Leukocyte Biol.*, 56:469-474, 1994.
6. Chen PW, Shreedhar VK, Ananthaswamy HN. Rejection of murine melanoma cells transfected with the intracellular adhesion molecule-1 gene. *Int. J. Oncology*, 6:675-680, 1995.
7. Chen PW, Geer DC, Podack ER, Ksander BR. Tumor cells transfected with B7-1 and Interleukin-12 cDNA induce protective immunity. *Interleukin-12. N.Y. Acad. Sci.*, 67:496-499, 1996.
8. Chen PW, Murray TG, Salgaller ML, Ksander BR. Expression of MAGE genes in ocular melanoma cell lines. *J. Immunother.*, 20: 265-275, 1997.
9. Chen PW, Murray TG, Uno T, Salgaller ML, Reddy R, Ksander BR. Expression of MAGE genes in ocular melanoma from primary to metastatic disease. *Clin. Exp. Metastasis*, 15:509-518, 1997.
10. Uno T, Chen PW, Murray TG, Podack ER, Ksander BR. Gene transfer of the CD80 costimulatory molecule into ocular melanoma cells using a novel episomal vector. *Invest. Ophthalmol. Vis. Sci.*, 38:2531-2539, 1997.
11. Ksander BR, Geer DC, Chen PW, Salgaller ML, Rubsam P, Murray TG. Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytes. *Curr. Eye Res.*, 17:165-173, 1998.

12. Wenkel H, Chen PW, Ksander BR, Streilein JW. Immune privilege is extended then withdrawn from allogenic tumor cell grafts placed in the subretinal space. *Invest. Ophthalmol. Vis. Sci.*, 40:3202-3208, 1999.
13. Ksander BR, Chen PW. Immunotherapy and gene therapy of uveal melanoma. *Ophthalmology Clinics of North America*, 12:1-14, 1999.
14. Chen PW, and Ksander BR. Immune privilege, tumors, and the eye - in "Regional Immunity and Ocular Immune Privilege", ed. JW Streilein. *Chemical Immunology Basel*, Karger., vol. 73, pp 137-154, 1999.
15. Ksander BR, Chen PW. Immunotherapy of uveal melanoma. *Immuno-Ophthalmology. Dev Ophthalmol.* eds. U Pleyer, M Zierhut, W Behrens-Baynann, Karger, Basel., pg 220-230, 1999.
16. Dissanayake SK, Thompson JA, Bosch JJJ, Clements VK, Chen PW, Ksander BR, Ostrand-Rosenberg, S. Activation of tumor-specific CD4⁺ T lymphocytes by MHC class II tumor cell vaccines: A novel cell-based immunotherapy. *Cancer Res.*, 64:1867-1874, 2004.
17. Chen PW, Ksander BR. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines. *Curr. Eye Res.*, 31: 43-55, 2006.
18. Chen PW, Ksander BR. Requirement of CD80⁺ costimulation for rejection of ocular tumors and termination of immune privilege. *Exp. Eye Res.*, 83: 574-583, 2006.
19. Chen PW, Uno T, Ksander BR. Tumor escape mutants develop within an immune privileged environment in the absence of T cell selection. *J. Immunol.*, 177:162-168, 2006.
20. Dace DS, Chen PW, Alizadeh H, Niederkorn JY. Ocular immune privilege is circumvented by CD4⁺ T cells, leading to the rejection of intraocular tumors in an IFN- γ dependent manner. *J. Leukocyte Biol.*, 81: 421-429, 2007.
21. Chen PW, Ksander BR, Influence of immune surveillance and immune privilege on formation of intraocular tumors. *Chemical Immunology and Allergy*, Vol. 92, 276 - 289, 2007.
22. Dace DS, Chen PW, Niederkorn JY. CD8⁺ T cells Circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF- α -dependent mechanism. *J. Immunol.*, 178: 6115-6122, 2007.
23. Dace DS, Chen PW, Niederkorn, JY. CD4⁺ T cell dependent tumor rejection in an immune privileged environment requires macrophages. *Immunology*, 123: 367-377, March 2008.
24. Chen PW, Mellon JK, Mayhew E, Wang, S, He Y, Hogan, N, and Niederkorn, JY. Uveal melanoma expression of indoleamine 2, 3 deoxygenase: Establishment of an immune privileged environment by tryptophan depletion. *Exp. Eye Res.*, 85: 617-625, 2007.

25. Yang W, Chen PW, Li H, Alizadeh H, and Niederkorn JY. PD-L1: PD-1 Interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. *Invest. Ophthalmol. Vis. Sci.*, 49:2518-2525, 2008.
26. Yang W, Li H, Chen PW, Alizadeh H, He Y, Hogan RN, and Niederkorn JY. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. *Invest. Ophthalmol. Vis. Sci.*, 50:273-280, 2009.
27. Niederkorn JY, Chen PW, Stevens CN, Mellon JK, Mayhew E. Allergic airway hyper-reactivity increases the risk for corneal allograft rejection. *Amer. J. Transplantation*, 9:1017-1026, 2009.
28. Li H, Yang W, Chen PW, Alizadeh H, Niederkorn JY. Inhibition of chemokine receptor expression on uveal melanoma cells by CXCR4 siRNA blocks tumor cell invasion and liver metastasis of uveal melanoma cells. *Invest. Ophthalmol. Vis. Sci.*, 50:5522-5528, 2009.
29. McKenna KC, Chen PW. Influence of immune privilege on ocular tumor development. *Ocular Immunol & Inflammation*, 18, 80–90, 2010.
30. Niederkorn JY, Chen PW, Mellon J, Stevens CN, Mayhew E. Allergic conjunctivitis exacerbates corneal allograft rejection by activating Th1 and Th2 alloimmune responses. *J. Immunol.*, 184, 6076-6083, 2010.
31. Ufret-Vincenty RL, Aredo B, Liu X, McMahon A, Chen PW, Sun H, Niederkorn JY, Kedzierski W. Transgenic mice expressing variants of complement factor H develop AMD-like retinal findings. *Invest. Ophthalmol. Vis. Sci.*, 51: 5878-5887, 2010.
32. Reyes NJ, Mayhew E, Chen PW, Niederkorn JY. NKT cells are necessary for maximal expression of allergic conjunctivitis. *Int. Immunol.*, 22:627-636, 2010.
33. Cunnusamy K, Chen PW, Niederkorn JY. Paradigm shifts in the role of CD4⁺ T cells in keratoplasty. *Discovery Med.*, 10:452-461, 2010.
34. Cunnusamy K, Paunicka K, Reyes N, Yang W, Chen PW, Niederkorn JY. Two different regulatory T cell populations that promote corneal allograft survival. *Invest. Ophthalmol. Vis. Sci.*, 51:6566-6574, 2010.
35. Cunnusamy K, Chen PW, Niederkorn JY. IL-17 Promotes immune privilege of corneal allografts. *J. Immunol.*, 185, 4651-4658, 2010.
36. Coursey TG, Chen PW, Niederkorn JY. Abrogating TNF- α expression prevents bystander destruction of normal tissues during iNOS-mediated elimination of intraocular tumors. *Cancer Res.*, 71:2445-2454, 2011.
37. Cunnusamy K, Chen PW, Niederkorn JY. IL-17A–Dependent CD4⁺CD25⁺ Regulatory T cells promote immune privilege of corneal allografts. *J. Immunol.*, 186: 6737-6745, 2011.
38. Yang W, Chen PW, Niederkorn JY. NKT cell exacerbation of liver metastases in mice with intraocular melanomas transplanted into the eyes or spleens of mice. *Invest. Ophthalmol. Vis. Sci.*, 52: 3094-3102.
39. Reyes NJ, Mayhew E, Chen PW, Niederkorn JY. $\gamma\delta$ cells are necessary for maximal expression of allergic conjunctivitis. *Invest. Ophthalmol, Vis. Sci.*, 52: 2211-2216, 2011.

40. Coursey TG, Chen PW, Niederkorn JY. IL-17-Dependent, IFN- γ -independent tumor rejection is mediated by CTLs and occurs at extraocular sites, but is excluded from the eye. *J. Immunol.*, 187: 4219-4228, 2011.

ABSTRACTS AND PRESENTATIONS:

1. Chen PW, Ananthaswamy HN. Immunotherapy of established murine melanoma using genetically modified tumor cells. [POSTER] *Cancer Res.*, 35:3078, 1994.
2. Chen PW, Geer DC, Podack ER, Ksander BR. Tumor cells transfected with B7-1+IL-12 cDNA induce lasting protective immunity. [MINISYMPOSIUM] *Cancer Res.*, Supplement 36:247, 1995.
3. Ksander BR, Murray T, Salgaller ML, Rosenberg SA, and Chen PW. Increased MAGE-1 expression on tumors that form within immune privileged sites of the eye. [POSTER] *Cancer Res.*, Supplement 36:478, 1995.
4. Ksander BR, Murray T, Rosenberg SA, Salgaller ML, Chen PW. Increased MAGE-1 expression on tumors that form within immune privileged sites within the eye. [POSTER] *J. Cellular Biochemistry*, Abstract supplement 21A, p.530, 1995.
5. Chen PW, Geer DC, Podack ER, Ksander BR. Tumor cells transfected with B7-1 + IL-12 cDNA induce lasting protective immunity. [MINISYMPOSIUM] *FASEB Journal*, 9, p.A494, 2860, 1995.
6. Chen PW, Salgaller ML, Rosenberg SA, Murray T, and Ksander BR. Increased expression of genes encoding tumor specific antigens in ocular melanoma: Potential targets for immunotherapy. [SPECIAL SYMPOSIUM], *Invest. Ophthalmol. Vis. Sci.*, 36, p.S221, 1009, 1995.
7. Ksander BR, Geer DC, Podack ER, Chen PW. Gene therapy using tumor cells transfected with B7-1 and IL-12 cDNA. *Invest. Ophth. Vis. Sci.*, [MINISYMPOSIUM], *Invest. Ophthalmol. Vis. Sci.*, 36, p.S845, 3887, 1995.
8. Chen PW, Geer DG, Podack ER, Ksander BR. Induction of memory T cells requires expression of B7-1 costimulatory molecule and secretion of IL-12. [WORKSHOP PRESENTATION] 9th International Congress of Immunology, San Francisco, 1995.
9. Chen PW, Uno T, Murray TG, Podack ER, Ksander BR. Gene therapy of ocular melanoma using a novel episomal system. [MINISYMPOSIUM] *Invest. Ophthalmol. Vis. Sci.*, 37, 5188, 1996.

10. Ksander BR, Murray TG, Uno T, Geer DC, Podack ER, Chen PW. Activation of tumor specific T cells by human ocular melanoma cells transfected with DNA for the B7.1 costimulatory molecule. [MINISYMPOSIUM] Invest. Ophthalmol. Vis. Sci., 37, 5127, 1996.
11. Chen PW, Uno T, Geer DC, Podack ER, Ksander BR. Protective immunity induced by B7.1+IL-12 transfected tumor cells is abrogated by tumor growth in an immune privileged site. [MINISYMPOSIUM] FASEB Journal, 10: A1164, 950, 1996.
12. Chen PW, Uno T, Geer DC, Podack ER, Ksander BR. Systemic immunity induced by B7.1+IL-12 transfected tumor cells is terminated by tumor growth within and immune privileged site. [POSTER SESSION] Cancer Vaccines International Symposium, 1996.
13. Chen PW, Uno T, Geer DC, Podack ER, Ksander BR. Effect of Immune Privilege on Cancer Vaccines. [POSTER SESSION] Keystone Symposium, Copper Mountain, Colorado, 1997.
14. Chen PW, Uno T, Murray TG, Ksander BR. MAGE expression in ocular melanomas during progression from primary to metastatic disease. [MINISYMPOSIUM] Invest. Ophthalmol. Vis. Sci., 38, 2163, 1997.
15. Uno T, Murray TG, Chen PW, Podack ER, Ksander BR. Gene transfer of the B7.1 costimulatory molecule into human ocular melanoma cells. [MINISYMPOSIUM] Invest. Ophthalmol. Vis. Sci., 38, 2161, 1997.
16. Ksander BR, Uno T, Geer DC, Podack ER, Chen PW. ACAID terminates systemic antitumor immunity induced by B7.1+IL-12 transfected tumor cells. [MINISYMPOSIUM] Invest. Ophthalmol. Vis. Sci., 38, 2272, 1997.
17. Ksander BR, Verbik DJ, Uno T, Chen PW, Podack ER, Murray TG. Gene therapy to prevent metastatic ocular melanoma. [SYMPOSIUM] International Symposium on Ocular Tumors, Tel Aviv, Israel, 1997.
18. Chen PW, Uno T, Ksander BR. Tumor cell escape mutants develop within immune privileged sites in the absence of T cell selective pressure. [POSTER] FASEB, Journal, 12, A283, 1651, 1998.
19. Ksander BR, Uno T, Chen PW. Establishing immune privilege at non-privileged extra-ocular sites. [MINISYMPOSIUM] Invest. Ophthalmol. Vis. Sci., 39, 4190, 1998.

20. Chen PW, Uno T, Ksander BR. Sight-preserving and sight-destroying elimination of tumors from the immune privileged anterior chamber. [MINISYMPOSIUM] Invest. Ophthalmol. Vis. Sci., 39, 4194, 1998.
21. Chen PW, Uno T, Murray TG, Ksander BR, Tumor antigen expression on uveal melanomas during progression from primary to metastatic disease. [MINISYMPOSIUM] XIII Int. Congress of Eye Res., Paris, France, 1998.
22. Chen PW, Uno T, Ksander BR, Tumor cell escape mutants that develop within immune privileged sites upregulate non-immunogenic immunodominant peptides [POSTER/DISCUSSION]. FASEB J., A613, 677, 1999.
23. Chen PW, Bilsborough J, Ksander BR. Ocular tumors escape elimination by establishing immune privilege at non-privileged sites. [POSTER]. Invest. Ophthalmol. Vis. Sci., 40, 4355, 1999.
24. Chen PW, Bilsborough J, Ksander BR. Tumor developing in an immune privileged environment escape elimination by altering presentation of immunogenic peptides. [POSTER] Keystone Symposium, Steamboat, CO., 2000.
25. Chen PW, Haskova Z, Taylor A, Ksander BR. Modulation of the class I pathway of antigen processing by the ocular environment – A novel mechanism for inducing tumor escape mutants. [POSTER] Cancer Vaccines International Symposium, 2000.
26. Chen PW, Stein-Streilein J, Ksander BR. Rejection of intraocular tumors requires termination of immune privilege through elimination of NKT cells. [POSTER] J. Leukocyte Biol., 2000.
27. Chen PW, Ksander BR. Termination of immune privilege during rejection of ocular tumors has a lasting impact on the ocular environment. [MINISYMPOSIUM] Invest. Ophthalmol. Vis. Sci., 41, 3105, 2000.
28. Geer DC, Murray TG, Ksander BR, Chen PW, Perez VL. Melastatin gene transcription and disease progression in uveal melanomas. [POSTER] Invest. Ophthalmol. Vis. Sci., 41, 2549, 2000.
29. Chen PW, Haskova Z, Taylor AW, Ksander BR. Modulation of antigen processing by the ocular environment generates tumor escape mutants. [WORKSHOP PRESENTATION] University of Leiden Medical Center Workshop : Immunobiology of Ocular Tumors, The Netherlands, 2001.

30. Chen PW, Haskova Z, Taylor AW, Ksander BR. Modulation of MHC Class I Antigen Processing by the Ocular Environment Generates Tumor Escape Mutants [MINISYMPOSIUM] X International Congress of Ocular Tumors, Amsterdam, The Netherlands, 2001.
31. Chen PW, Haskova Z, Taylor AW, Ksander BR. Aqueous humor alters the antigen repertoire presented by class I on ocular tumors. [POSTER] Invest. Ophthalmol. Vis. Sci., 42, 2549, 2001.
32. Hatton MP, Chen PW, Wistow G, Perez VL, Ksander BR. Melastatin-2 gene transcription in normal and malignant uveal melanoma. [MINISYNPOSIUM] Invest. Ophthalmol. Vis. Sci., 42, 598, 2001.
33. Chen PW, Haskova Z, Taylor AW, Ksander BR. Ocular tumors escape immune recognition when aqueous humor imprints genes that control antigen processing. [MINISYMPOSIUM] Invest. Ophthalmol. Vis. Sci., 43, 843, 2002.
34. Bosch JJJ, Chen PW, Mensink HM, Jager MJ, Murray TG, Ksander BR. Microarray analysis of differential gene expression in autologous primary and metastatic uveal melanoma. [MINISYMPOSIUM] Invest. Ophthalmol. Vis. Sci., 43, 1860, 2002.
35. Bosch JJJ, Chen PW, Mensink HM, Jager MJ, Murray TG, Ksander BR. Microarray analysis of differential gene expression in autologous primary and metastatic uveal melanoma. [POSTER] Cancer Res., Supplement 43:468, 2002.
36. Chen PW, Haskova Z, Taylor AW, Ksander BR. Ocular tumors escape immune elimination when aqueous humor induces methylation of genes that control antigen processing. [POSTER] Cancer Res., Supplement 73, 43:16, 2002.
37. Chen PW, Bosch JJJ, Dissayanake S, Thompson J, Ostrand-Rosenberg S, Ksander BR. Genetic modification of a human tumor to express HLA class II heterodimers in the absence of invariant chain. [POSTER] Keystone Symposium, Keystone, CO, 2003.
38. Chen PW, Bosch JJJ, Dissayanake S, Thompson J, Ostrand-Rosenberg S, Ksander BR. Class II in the absence of invariant chain on uveal melanomas – a pathway to present endogenous tumor antigens. [POSTER] Invest. Ophthalmol. Vis. Sci., 44, 760, 2003.
39. Mensink HM, Chen PW, Lindenhovius CL, Jager MJ, Ksander BR. Ocular tumor escape in transgenic mice with a high percentage of tumor antigen specific CD8+ T cells. [POSTER] Invest. Ophthalmol. Vis. Sci., 44, 765, 2003.

40. Chen PW, Chun LLY, Ksander BR. The ocular environment induces epigenetic changes in tumor cells that leads to immune escape. [MINISYMPOSIUM] Invest. Ophthalmol. Vis. Sci., 46, 4521, 2004.
41. Niederkorn JY, Dace DS, Chen PW, Alizadeh H. Role of interferon-gamma in intraocular tumor rejection. [MINISYMPOSIUM] Invest. Ophthalmol. Vis. Sci., 47, 2920, 2006.
42. Niederkorn JY, Beauregard C, Chen PW, Stevens C, Mellon J. Increased incidence and accelerated corneal allograft rejection in mice with allergic conjunctivitis requires both Th1 and Th2 cells and the Th1 cytokine, interferon-gamma. [MINISYMPOSIUM] Invest. Ophthalmol. Vis. Sci., 48, 192, 2007.
43. Chen PW, Dace, DS, Alizadeh H, Niederkorn JY. Influence of the immune privileged ocular microenvironment on the immune rejection of intraocular tumors. Keystone Symposia: Inflammation, Microenvironment and Cancer, [POSTER] 2008.
44. Yang W, Chen PW, Alizadeh H, Niederkorn JY. PD-L1 expression by uveal melanoma inhibits T-cell IL-2 synthesis. [POSTER] Invest. Ophthalmol. Vis. Sci., 49, 2008.
45. Stevens C, Chen PW, Mellon JS, Mayhew, E, Niederkorn JY. CD4⁺ CD25⁺ regulatory cells contribute to the immune privilege of corneal allografts. [POSTER] Invest. Ophthalmol. Vis. Sci., 49, 2008.
46. Ufret-Vincenty R, McMahon A, Chen PW, Niederkorn, JY, Kedzierski W. Generation and characterization of chimeric complement factor H transgenic mice with an "At Risk" mutation for age-related macular degeneration. [POSTER] Invest. Ophthalmol. Vis. Sci., 49, 2008.
47. Niederkorn JY, Chen PW, Stevens C, Mellon J, Mayhew E. Th2-mediated airway hyperactivity exacerbates corneal allograft rejection. [MINISYMPOSIUM] Invest. Ophthalmol. Vis. Sci., 49, 2008.
48. Chen PW, Dace DS, Alizadeh H, Niederkorn JY. Tumor infiltrating CD8⁺ T cell mediate non-phthical intraocular tumor rejection by TNF- α dependent mechanism. [PAPER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 49, 2008.
49. Chen PW. Epigenetic gene regulation by the ocular microenvironment. [WORKSHOP PRESENTATION] Invest. Ophthalmol. Vis. Sci., 49, 2008.
50. Chen PW, Ksander BR, Li H-C, Mellon JS, Yang W. The ocular microenvironment utilizes de novo methylation to generate tumor escape mutants by an epigenetic mechanism. [WORKSHOP PRESENTATION] Invest. Ophthalmol. Vis. Sci., 50, 2009.
51. Li H, Yang W, Alizadeh H, Chen PW, Niederkorn JY. Inhibition of uveal melanoma metastasis by suppression of CXCR4 expression. [POSTER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 50, 2009.

52. Niederkorn JY, Chen PW, Stevens C, Mellon J, Mayhew E. Allergic asthma exacerbates corneal allograft rejection mediated by a mixed Th1 and Th2 alloimmune response [PAPER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 50, 2009.
53. Aredo B, McMahon A, Chen P, Niederkorn JY, Sun H, Botto M, Kedzierski W, Ufret-Vincenty R. Towards a mouse model of AMD: Chimeric complement factor H molecules carrying the Y402H variants are functional *in vivo*. [POSTER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 50, 2009.
54. Steven P, Huettmann G, Gebert A, Siebelmann S, Koop N, Chen P, Niederkorn JY. Ultrastructure and function of conjunctiva-associated lymphoid tissue in a novel mouse model. [POSTER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 50, 2009.
55. Coursey TG, Chen PW, Niederkorn JY. Role of TNF- α and iNOS in CD4⁺ T cell-mediated immune responses that reject intraocular tumors but destroy the eye. [POSTER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 51, 2010.
56. Aredo B, McMahon A, Chen PW, Niederkorn JY, Hong H, Salomon RG, Kedzierski W, Ufret-Vincenty R. AMD-like changes in CFH transgenic mice: Can antigen-specific immunity enhance the phenotype? [POSTER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 51, 2010.
57. Cunnusamy K, Chen PW, Niederkorn JY. Corneal allograft survival requires interplay between T regulatory cells and Interleukin-17A. [POSTER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 51, 2010.
58. Reyes NJ, Mayhew E, Chen PW, Niederkorn JY. Innate T cells are necessary for maximal expression of allergic conjunctivitis. [POSTER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 51, 2010.
59. Niederkorn JY, Cunnusamy K, Chen PW, Yang W. Interleukin-17 promotes immune privilege of corneal allografts. [PAPER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 51, 2010.
60. Chen PW, Sadegh L, Li H. Epigenetic induction of dimethylation and trimethylation at histone 3, lysine-4 residues by the ocular microenvironment. [PAPER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 51, 2010.
61. Reyes NJ, Chen PW, Niederkorn JY. The role of allergic conjunctivitis in the exacerbation of corneal allograft rejection. [POSTER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 52, 2011.
62. Cunnusamy K, Chen PW, Niederkorn JY. CD4⁺ CD25⁺ T regulatory cells in the establishment of corneal immune privilege. [POSTER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 52, 2011.
63. Chen PW, Sadegh L, Niederkorn JY. Epigenetic regulation of CXCR4 expression by the ocular environment. [POSTER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 52, 2011.

64. Paunicka K, Niederkorn JY, Chen PW. CD8⁺ regulatory T cells require IFN γ to mediate anterior chamber-associated immune deviation (ACAID) suppression. [POSTER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 52, 2011.
65. Niederkorn JY, Coursey TG, Chen PW. Role of IFN γ and IL-17 in the immune rejection of intraocular tumors. [PAPER PRESENTATION] Invest. Ophthalmol. Vis. Sci., 52, 2011.